Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will hold a conference call and live webcast on February 22, 2022, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2021 financial results and provide a corporate update.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will hold a conference call and live webcast on February 22, 2022, at 8:30 a.m. ET to discuss its fourth quarter and full-year 2021 financial results and provide a corporate update. The event aims to inform investors and the public about the company's performance and strategies. A live webcast will be available on its website, with a replay accessible within 48 hours. Kiniksa focuses on developing therapeutic medicines for diseases with significant unmet needs, utilizing innovative assets like ARCALYST and mavrilimumab.
Positive
- Company to provide full-year 2021 financial results and corporate updates.
- Focus on developing therapeutic medicines for unmet medical needs.
Negative
- None.
Details
News Market Reaction – KNSA
The recorded move for KNSA in the trading session of this news was -0.93%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAMILTON, Bermuda, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 22, 2022, at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2021 financial results and corporate update.
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours of the event. The conference call can be accessed by dialing (866) 614-0636 (U.S. and Canada) or (409) 231-2053 (international) using conference ID number 8145539.
About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio assets, ARCALYST®, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.
| Every Second Counts! ® Kiniksa Investor and Media Contact Rachel Frank (339) 970-9437 rfrank@kiniksa.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.